HER2-negative breast cancer

This study tests whether giving 6 months of hormone therapy before surgery helps remove all cancer cells in women with early-stage, estrogen-positive breast cancer. It involves 8 postmenopausal women with low-risk, node-negative tumors. The goal is to see if this approach leads t…

This trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…

This pilot study tests whether adding a special heat therapy (multimodal thermal therapy) to standard chemotherapy and immunotherapy can help the immune system better recognize and attack HER2-negative breast cancer. The study enrolls women aged 18–70 with certain subtypes of bre…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This study tested a new chemotherapy drug called WH002 against the standard drug paclitaxel in 40 women with HER2-negative breast cancer. Both drugs were given before surgery, followed by two other chemotherapy drugs. The main goal was to compare side effects and how well the tum…

This early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…

This study tested a new oral drug called OP-1250 in 153 adults with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer. The drug works by blocking estrogen receptors more completely than current therapies. The trial aimed to find the best dose, check sa…

This study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…

This study looked at whether adding a drug that targets specific genetic changes in breast tumors could slow cancer growth more than standard hormone therapy alone. It involved 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal…